PAS
CGEM icon

Point72 Asia (Singapore)’s Cullinan Oncology CGEM Stock Holding History

Point72 Asia (Singapore)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,852
Closed -$29.1K – 1079
2023
Q4 		$29.1K Buy
+2,852
New +$25.3K 0.01% 391

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Point72 Asia (Singapore)'s CGEM Position: Q1 2024 in Review

Point72 Asia (Singapore) sold out of Cullinan Oncology (CGEM) in Q1 2024, closing a stake of 2,852 shares — an estimated $29.1K sold.

Point72 Asia (Singapore) first reported a position in CGEM in Q4 2023 and held it in 1 quarter. The position peaked at $29.1K in Q4 2023. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

  • Point72 Asia (Singapore) reported no remaining Cullinan Oncology position as of Q1 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 2,852 Cullinan Oncology shares in Q1 2024, an estimated $29.1K.
  • Point72 Asia (Singapore) first reported a position in Cullinan Oncology in Q4 2023 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Cullinan Oncology position peaked at $29.1K in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2024, filed 15 May 2024.